Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sunobinop - Imbrium Therapeutics/Shionogi

Next Previous
Drug Profile

Sunobinop - Imbrium Therapeutics/Shionogi

Alternative Names: IMB-115; IMB-115 tosylate; IT-1315; RSC117957; S-117957; Sunobinop tosylate; V-117957

Latest Information Update: 12 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Purdue Pharma; Shionogi
  • Developer Imbrium Therapeutics; Purdue Pharma; Shionogi
  • Class Analgesics; Aza compounds; Carboxylic acids; Drug withdrawal therapies; Quinoxalines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Nociceptin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Alcoholism; Insomnia; Interstitial cystitis
  • No development reported Fibromyalgia; Overactive bladder
  • Discontinued Dental pain; Neuropathic pain

Most Recent Events

  • 09 Sep 2025 Adverse events and efficacy data from a phase I trial in interstitial cystitis released by Imbrium Therapeutics
  • 28 Jul 2025 No recent reports of development identified for phase-I development in Overactive bladder in USA (PO)
  • 14 Jul 2025 Imbrium Therapeutics completes enrolment in a phase-II trial for Alcoholism in the USA (PO) (NCT06545929)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top